Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Oct 15, 2018 Theratechnologies Appoints New Board Member Oct 04, 2018 Theratechnologies Announces Financial Results for the Third Quarter of 2018 Oct 03, 2018 PHARMACOKINETIC PROFILE OF TROGARZOTM PRESENTED AT IDWEEK Sep 28, 2018 THERATECHNOLOGIES’ CFO TO ATTEND CANTOR GLOBAL HEALTHCARE CONFERENCE IN NEW YORK CITY Sep 28, 2018 LYNE FORTIN TO LEAVE THERATECHNOLOGIES BY YEAR-END Sep 27, 2018 THERATECHNOLOGIES TO ANNOUNCE FINANCIAL RESULTS FOR THIRD QUARTER 2018 Sep 14, 2018 EUROPEAN MEDICINES AGENCY VALIDATES MARKETING AUTHORIZATION APPLICATION FOR TROGARZO™ Sep 05, 2018 FDA CONFIRMS TARGET DECISION DATE FOR NOVEL SINGLE-VIAL FORMULATION OF EGRIFTA® (TESAMORELIN FOR INJECTION) Aug 28, 2018 THERATECHNOLOGIES FILES MARKETING AUTHORIZATION APPLICATION FOR TROGARZO™ IN EUROPE Aug 20, 2018 EUROPEAN MEDICINES AGENCY AUTHORIZES DEFERRAL OF PAEDIATRIC INVESTIGATION PLAN FOR TROGARZO™ First page « Previous page ‹ … Page 21 Page 22 Page 23 Page 24 Current page 25 Page 26 Page 27 Page 28 Page 29 … Next page › Last page » Displaying 241 - 250 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Sep 05, 2018 FDA CONFIRMS TARGET DECISION DATE FOR NOVEL SINGLE-VIAL FORMULATION OF EGRIFTA® (TESAMORELIN FOR INJECTION)
Aug 20, 2018 EUROPEAN MEDICINES AGENCY AUTHORIZES DEFERRAL OF PAEDIATRIC INVESTIGATION PLAN FOR TROGARZO™
